Takeda and Indonesia Partner on $30M Plasma Hub to Boost Regional Healthcare Supply
Event summary
- Takeda will invest $30M in a two-year pilot program to establish plasma donation centers in Indonesia, with the first expected to open in 2027.
- The collaboration includes a fractionation license granted by Indonesia's Ministry of Health and aims to position Indonesia as a regional hub for plasma science and biopharmaceutical manufacturing.
- Takeda will assess feasibility for a state-of-the-art plasma-derived therapy manufacturing facility in Indonesia, potentially serving global supply chains.
The big picture
This collaboration addresses critical gaps in Southeast Asia's healthcare supply chain, particularly for plasma-derived therapies. By leveraging Indonesia's strategic location and Takeda's global expertise, the partnership aims to create a sustainable model for regional healthcare resilience. The initiative also aligns with Indonesia's broader ambitions to become a hub for advanced biopharmaceutical manufacturing.
What we're watching
- Regulatory Alignment
- Whether Indonesia's regulatory framework can support the scale-up of plasma-derived therapy manufacturing to international standards.
- Execution Risk
- The pace at which Takeda can operationalize plasma donation centers and transfer technology while meeting domestic healthcare needs.
- Market Expansion
- How this initiative will affect Takeda's position in the ASEAN region's growing demand for plasma-derived medicinal products.